NS Pharma steals a march on Sarepta with DMD drugJapan’s Nippon Shinyaku Pharma has filed for approval of its Duchenne muscular dystrophy (DMD) in the US, increasing Share XNS Pharma steals a march on Sarepta with DMD drughttps://pharmaphorum.com/news/ns-pharma-steals-a-march-on-sarepta-with-dmd-drug/
FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stableThe FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential Share XFDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stablehttps://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/
Sarepta DMD gene therapy could improve patients’ motor functionSarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase Share XSarepta DMD gene therapy could improve patients’ motor functionhttps://pharmaphorum.com/news/sarepta-dmd-gene-therapy-could-improve-patients-motor-function/
Curing DMD: Travelling together to find a meaningful destinationFor many years, Duchenne muscular dystrophy (DMD) was something of a forgotten disease. The boys, and some girls, Share XCuring DMD: Travelling together to find a meaningful destinationhttps://pharmaphorum.com/disease-spotlight/dmd-main/curing-dmd-travelling-together-to-find-a-meaningful-destination/
Increase collaboration to widen access to DMD drugs, trials and careWhen it comes to fighting a rare disease like Duchenne muscular dystrophy (DMD), it’s a matter of strength Share XIncrease collaboration to widen access to DMD drugs, trials and carehttps://pharmaphorum.com/disease-spotlight/increase-collaboration-to-widen-access-to-dmd-drugs-trials-and-care/
Pfizer axes development of Duchenne muscular dystrophy antibodyPfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy Share XPfizer axes development of Duchenne muscular dystrophy antibodyhttps://pharmaphorum.com/news/duchenne-trials-axed-pfizer-dmd/
Sarepta dives deeper into gene therapySarepta Therapeutics has handed $30 million to Lacerta in exchange for a group of gene therapies, including a Share XSarepta dives deeper into gene therapyhttps://pharmaphorum.com/news/sarepta-dives-deeper-gene-therapy/
Parenting as a DMD patientParenting as a DMD patient The sleepless nights and steep learning curve that will be familiar to any Share XParenting as a DMD patienthttps://pharmaphorum.com/views-analysis-digital/parenting-as-a-dmd-patient/
He ain’t heavy – learning about a sibling’s DMD diagnosisIt’s common for patients to want to know more about what’s causing them to be ill and their Share XHe ain’t heavy – learning about a sibling’s DMD diagnosishttps://pharmaphorum.com/views-and-analysis/learning-sibling-dmd-diagnosis/
